发明名称 |
Potentiating antibody-induced complement-mediated cytotoxicity via PI3K inhibition |
摘要 |
<p>Methodologies and technologies for potentiating antibody-based cancer treatments by increasing complement-mediated cell cytotoxicity are disclosed. Further provided are methodologies and technologies for overcoming ineffective treatments correlated with and/or caused by sub-lytic levels of complement-activating monoclonal antibodies ("mAb") against cancer antigens or cancer antigens with low tumor cell density. While detectable levels of passively administered or vaccine-induced mAb against some antigens are able to delay or prevent tumor growth, low levels of mAb induce sublytic levels of complement activation and accelerate tumor growth. This complement-mediated accelerated tumor growth initiated by low mAb levels results in activation of the PI3K/AKT survival pathway. Methodologies and technologies relating to administration of PI3K inhibitors to overcome low dose mAb-initiated, complement-mediated PI3K activation and accelerated tumor growth are disclosed.</p> |
申请公布号 |
AU2013235479(A1) |
申请公布日期 |
2014.10.02 |
申请号 |
AU20130235479 |
申请日期 |
2013.03.14 |
申请人 |
MEMORIAL SLOAN-KETTERING CANCER CENTER |
发明人 |
WU, XIAOHONG;SCHOLZ, WOLFGANG W.;RAGUPATHI, GOVIND;LIVINGSTON, PHILIP O. |
分类号 |
A61K39/395;A61K39/00 |
主分类号 |
A61K39/395 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|